Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
Kevin Kalinsky MD, MS
Komal Jhaveri, MD, FACP
Advancing Myasthenia Gravis (MG) Treatment Through Guideline Updates and Emerging Therapies
October 30, 2025
San Francisco, California
What’s New In Glaucoma?
Paul Petrakos, DO, MS
Justin Schweitzer, OD, FAAO
I. Paul Singh, MD
Sarah H. Van Tassel, MD
Time Is Bone: Making the Case for Early Anabolic Treatment in Osteoporosis
Kendall Moseley, MD
Kenneth G. Saag, MD
Trial in Progress: Phase 3 MoonRISe-3 Study
First Results From Cohort 4 of the SunRISe-1 Trial
Treatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics
Vera Bril, MD
Neelam Goyal, MD
Revolutionizing Diagnostic Precision: AI-Driven Approaches in Digital Pathology and HER2 Expression
Marilyn Yuanxin Ma Bui, MD, PhD
Anne Vincent-Salomon, MD
HER2 in Bladder Cancer: Breaking Through the Molecular Frontier
Vadim S. Koshkin, MD
Chairperson's Perspective: Innovative Approaches to IBS-C: Personalized Treatment for Better Outcomes
Darren Brenner, MD
Managing Side Effects in FcRn Therapy: Best Practices for gMG
Nicholas J. Silvestri, MD
Treatment Advances in Generalized Myasthenia Gravis: Addressing the Nuances of its Underlying Immunopathology
Hans Katzberg, MD
Preventing Myasthenic Crisis: Early Signs and Critical Interventions
Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection
Jonathan Strober, MD
Non-CF Bronchiectasis: How Radiologists Can Drive Better Outcomes
Robert D. Suh, MD
Lea Azour, MD
Ashwin Basavaraj, MD
Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
Neal Shore, MD, FACS
Sarah Psutka, MD, MS
From Doctor-Speak to Patient-Speak: Bridging the Communication Gap
Luis A. Gonzalez, MD, MPH
Jeremiah Brown Jr., MD, MS, FASRS
New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy
Autoantibodies Explained: Anti-AChR, Anti-MuSK, and Their Diagnostic Role
Traditional MG Treatments: Balancing Benefits, Risks, and Side Effect Management
New Strategies for Individualizing Treatment in DME
SunRISe-1: 1-Year Durability and Patient-Reported Outcomes Results
Ocular to Generalized MG: How and Why the Disease Evolves
Living with gMG: Navigating Personal, Professional, and Mental Health Challenges
Diagnostic Advances in gMG: Effective Tools and Techniques
Collaborative Insights to Solve the Puzzle of Bladder Cancer
Daniel P. Petrylak, MD
Elizabeth R. Plimack, MD, MS, FASCO
Evan Y. Yu, MD
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.